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T lymphocytes play a critical part in inflammatory
skin diseases but are targeted by available therapies
that have only partial efficacy, significant side-effects,
or both. Because psoriasis, atopic dermatitis, and
allergic contact hypersensitivity are associated with T
helper type 1 (Th1), T helper type 2 (Th2), or mixed
Th1–Th2 cell subsets and cytokine types, respec-
tively, there is a need for a better broad-based inhibitor.
The macrolactam ascomycin analog, ABT-281, was
found to inhibit potently T cell function across species
and to inhibit expression of multiple cytokines in
human peripheral blood leukocytes which have been
found in human skin disease cells and tissues. These
included immunoregulatory Th1 (interleukin-2 and
interferon-g) and Th2 (interleukin-4 and interleukin-
5) cytokines. ABT-281 was shown to have potent
topical activity (ED50 J 0.6% in acetone/olive oil) in
a stringent swine model of allergic contact hyper-
sensitivity, but its potency was markedly reduced
compared with ascomycin when administered
Inflammatory skin diseases continue to be a major medicalproblem for which current therapy is inadequate. Psoriasishas a prevalence of 1%–2% (Phillips and Dover, 1992;Sander et al, 1993). Atopic dermatitis affects similar numbers,including almost 10% of all children (Charlesworth, 1994).
Although attention in psoriasis has, for many years, been focused
on its profound keratinocyte hyperplasia, most current therapeutics
have been found to have inhibitory effects on cellular immune
responses and inflammation, including UV irradiation, cortico-
steroids, methotrexate, anthralin, retinoids, and cyclosporine
(Gottlieb, 1988; Griffiths and Voorhees, 1996). Although therapy
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systemically due to more rapid clearance. Topical
application of 3% ABT-281 in acetone/olive oil over
25% of the body surface in swine resulted in undetect-
able blood levels. Compared with a wide potency range
of topical corticosteroids in clinical formulations, 0.3%
and 1% ABT-281 ointments profoundly inhibited
dinitrochlorobenzene-induced contact hypersensi-
tivity in the pig by 78% and 90%, respectively, whereas
super-potent steroids such as clobetasol propionate
only inhibited in the 50% range and mild to moderate
potency steroids such as fluocinolone acetonide were
inactive. The potent topical activity of ABT-281 in
swine, its superior efficacy, its rapid systemic
clearance following uptake into the bloodstream, and
its ability to inhibit cytokine biosynthesis of both
Th1 and Th2 cell subsets, suggests that it will have
a broad therapeutic value in inflammatory skin
diseases, including psoriasis, atopic dermatitis, and
allergic contact dermatitis. Keywords: atopic dermatitis/
contact dermatitis/corticosteroids/psoriasis. J Invest Dermatol
112:729–738, 1999
has advanced towards agents with ever-increasing inhibitory speci-
ficity for the T cell, perhaps best illustrated by cyclosporine, which
has superior efficacy but is limited by toxicity to low-dose or
intermittent use (Powles et al, 1993; Laburte et al, 1994; Mahrle
et al, 1995), no systemic agent is available that is both safe and
highly efficacious.
The accessibility of the skin to topical therapy provides an
opportunity to exploit the effects of potent agents that would
otherwise be too toxic. Unfortunately, cyclosporine does not work
topically in psoriasis due to its apparent poor ability to penetrate
the skin (Lebwohl et al, 1995). Topical corticosteroids can provide
symptomatic relief, but only potent and super-potent steroids are
effective, and these carry a risk of local side-effects, e.g., skin
thinning (Stoughton and Cornell, 1993). Also, tachyphylaxis has
been observed with long-term use of topical steroids, and they
have been judged less effective than available phototherapy or
systemic therapy (Liem et al, 1995). The vitamin D analog calcipo-
triene (calcipotriol) typically gives 50%–60% improvement and has
a high incidence of skin irritation (15%–25% of patients), although
the latter is typically mild (Lea and Goa, 1996). Phototherapy
(psoralen ultraviolet A, ultraviolet B) has good efficacy in psoriasis
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(Spuls et al, 1997), but can damage the skin over the long term
and significantly increase cancer incidence. Tars and anthralin,
although still used, have low efficacy, are messy and inconvenient,
and also have carcinogenic potential (Liem et al, 1995).
The first-line therapy for atopic dermatitis emphasizes environ-
mental control to avoid inciting disturbances to the skin and liberal
use of emollients to control water loss (Cooper, 1994; Hanifin and
Chan, 1996). A number of agents used in psoriasis can benefit the
atopic dermatitis patient, including phototherapy, methotrexate,
cyclosporine, and corticosteroids, but are limited by the disadvant-
ages described above for psoriasis therapy. Current management of
allergic contact dermatitis involves elimination of the allergen where
possible but still depends heavily on the use of systemic or topical
corticosteroids with their inherent problems and limitations (Funk
and Maibach, 1994).
Establishment of an immune basis for these major skin diseases
has evolved from evidence linking efficacy of the above therapeutics
to inhibition of T lymphocyte function, both in psoriasis (Gottlieb
et al, 1992, 1995; Vallat et al, 1994; Jeffes et al, 1995; Krueger et al,
1995; Menssen et al, 1995) as well as in atopic dermatitis (Cooper,
1994; Van Joost et al, 1992; Hanifin, 1996). In addition, immune
cells from psoriasis patients have been shown to induce a psoriatic
phenotype in symptomless skin grafted onto SCID mice (Wrone-
Smith and Nickoloff, 1996). As a framework for understanding the
diverse effects of immune cells, T helper cells can be classified into
two phenotypes defined by their cytokine-releasing profiles: T
helper type 1 (Th1) cells produce interleukin (IL)-2 and interferon
(IFN)-γ, whereas T helper type 2 (Th2) cells make IL-4, IL-5, and
IL-10 (Mosmann et al, 1986). These immunoregulatory cytokine
subsets have mutually inhibitory and self-stimulatory roles in
addition to recruiting other effector cells in a selective fashion to
produce inflammatory mediators and chemokines. Various
immunologic diseases have been characterized as Th1 or Th2
mediated because they display a predominance of one phenotype,
presumably representing a pathologic dysregulation. In psoriasis,
there are primarily Th1 cells in the skin (Uyemura et al, 1993;
Schlaak et al, 1994), whereas atopic dermatitis is characterized by
presence of Th2 cells and their respective cytokines, as has been
reviewed (Cooper, 1994; Leung, 1997). This paradigm can explain
why skin diseases that have an immunologic basis, such as atopic
dermatitis and psoriasis, can have diverging symptoms, but is
nonetheless an oversimplification as illustrated by the recovery from
psoriatic skin of cells expressing mixed Th1 and Th2 cytokines
(Vollmer et al, 1994) as well as evidence that both Th1 and Th2
cells may play a part in atopic dermatitis, perhaps acting sequentially
(Grewe et al, 1998). It should also be mentioned that there is
growing evidence of immune cell involvement in irritant contact
dermatitis (Brand et al, 1995), and its clinical presentation and
chronicity may be the result of a pathophysiologic dysregulation
of immune cells in the skin (Brasch et al, 1992).
In view of this complexity, a therapeutic agent with broad
applicability to the major inflammatory skin diseases would need
to downregulate both Th1 and Th2 cytokine production. Topical
tacrolimus, an agent shown in animal models to inhibit mRNA
levels of a number of Th1 and Th2 cytokines (Homey et al, 1998)
was found to be effective in reducing lesion scores in atopic
dermatitis (Ruzicka et al, 1997), but not in chronic plaque psoriasis
(Zonneveld et al, 1998). This paper describes ABT-281 (Fig 1), an
immunomodulatory agent of the ascomycin class (Hatanaka et al,
1988), which has anti-inflammatory activity by potently inhibiting
biosynthesis of multiple cytokines, including both Th1 and Th2
types. ABT-281 was found to have potent effects on T cells from
multiple species and, despite its size (molecular weight 5 844), it
was topically active in animal models of allergic contact dermatitis,
including a stringent swine model believed to resemble human
skin in presenting a challenging barrier to drug penetration (vide
infra). An interesting aspect of its behavior is that it is cleared more
rapidly from the systemic circulation, and thus has a very favorable
overall profile for topical use in skin disease therapy.
Figure 1. Chemical structures of ascomycin and ABT-281. The
macrolactam ring nucleus common to both is shown. R, OH for ascomycin;
R, epi-N1-tetrazolyl for ABT-281.
MATERIALS AND METHODS
Reagents Histopaque-1077, mitomycin C, RPMI-1640, L-glutamine,
gentamycin, nonessential amino acids, 2-mercaptoethanol, and p-nitro-
phenyl phosphate were purchased from Sigma (St. Louis, MO). Serum-
free AIM-V medium, 1% Antibiotic-Antimycotic Solution, Dulbecco’s
phosphate-buffered saline (DPBS), penicillin, and streptomycin were pur-
chased from GIBCO BRL (Grand Island, NY). Fetal bovine serum (FBS)
was purchased from Hyclone (Logan, UT), and [3H]thymidine from
DuPont NEN (Boston, MA). Sterile 0.9% saline was obtained from Abbott
Laboratories (Abbott Park, IL). Ascomycin was purified from a fermentation
of Streptomyces hygroscopicus ssp. ascomyceticus ATCC 14891 and characterized
as described previously (Or et al, 1993). ABT-281 was prepared from
ascomycin by semisynthesis. Trifluoromethanesulfonyl anhydride (0.28 g
in 1 ml dry dichloromethane) was added into a stirred solution of
ascomycin (0.8 g) and diisopropylethyl amine (0.5 g) in dichloromethane
(2 ml) at –15°C. After stirring for 0.5 h, tetrazole (0.1 g) was added and
stirring continued at room temperature for 24 h. Solvent was removed in
vacuo and the crude material purified by silica gel (40 g) eluting with 40%
acetone/hexanes. The product was further purified by silica gel (40 g)
eluting with 3% isopropanol/dichloromethane.
The following corticosteroids were tested in their clinical formulations
and are listed with their generic names: Temovate ointment (0.05%
clobetasol propionate; Glaxo-Wellcome), Diprolene ointment and
Diprolene AF cream (0.05% betamethasone equivalence in the dipropionate
form; Schering), Lidex ointment (0.05% fluocinonide; Medicis), Aristocort
A ointment (0.1% triamcinolone acetonide; Fujisawa), Synalar oint-
ment (0.025% fluocinolone acetonide; Medicis), Valisone cream (0.1%
betamethasone valerate; Alpharma), Aristocort A cream (0.1% triamcinolone
acetonide; Fujisawa), Hytone ointment (2.5% hydrocortisone; Dermik),
and Dovonex ointment (0.005% calcipotriene; Westwood-Squibb). ABT-
281 was prepared for testing in an ointment at 0.3% and 1% concentrations.
Animals All animal protocols were approved by an Institutional Animal
Care and Use Committee. Male Lewis and Brown-Norway rats, 170–
190 g, and Hartley guinea-pigs, 300–400 g, were purchased from Harlan
(Indianapolis, IN). Male Sprague–Dawley rats, 225–300 g, and male mice,
18–21 g, were purchased from Charles River (Wilmington, MA). Female
Landrace/Jersey White cross-bred pigs, 8–10 wk of age (7–9 kg), were
purchased from Wilson (Prairie View) Farm (Burlington, WI). Rats and
mice were killed by CO2 inhalation.
Human mixed leukocyte reaction (MLR) assay Fifty milliliters of
sodium heparinized blood, obtained from four normal, unrelated donors,
was mixed with an equal volume of DPBS. Peripheral blood mononuclear
cells (PBMC) were isolated by density centrifugation at 400 3 g over
Histopaque-1077. A sufficient number of PBMC from two individuals
were washed three times in RPMI-1640 medium and used as responder
cells. The remaining PBMC (stimulator cells) were washed as above and
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treated with 25 µg per ml of mitomycin C for 30 min at 37°C in an
atmosphere of 5% CO2 and 100% humidity and then washed three times
in RPMI-1640 medium. The stimulator cells were pooled at 0.5–1.0 3 106
cells per ml per donor in RPMI-1640 medium. Cells were cultured in
medium consisting of RPMI-1640 supplemented with 4 mM L-glutamine,
50 µM 2-mercaptoethanol, 10% FBS, 25 units per ml penicillin, and 25 µg
per ml streptomycin. Mixed leukocyte reactions were performed in 96
well flat-bottom plates (Corning, Acton, MA) in a final volume of 220 µl
containing 20 µl of culture medium with or without test compound,
100 µl of responder cells (1 3 106 cells per ml) and 100 µl of stimulator
cells (2–4 3 106 cells per ml). Cultures were incubated at 37°C in an
atmosphere of 5% CO2 and 100% humidity for 4 d. On day 4, 0.5 µCi
of [3H]thymidine was added to each well during the last 6 h of culture.
Cultures were harvested onto glass-fiber filter mats using a 96 well harvester
(Tomtec, Orange, CT). [3H]Thymidine uptake was measured by direct
β-counting using a Matrix 9600 β-counter (Packard, Meriden, CT).
ABT-281 inhibition of IL-2 production in human whole blood and
PBMC Fifty milliliters of venous blood from normal donors was drawn
into tubes containing sodium heparin. Twenty-five milliliters of blood was
used directly. PBMC were isolated from the remaining sample as described
above and cultured at 1 3 106 cells per ml with supplemented RPMI
1640. Whole blood or PBMC were induced to secrete IL-2 with 50 ng
PMA per ml plus 1 µg ionomycin per ml. Immunosuppressive potency of
ABT-281 was determined by measuring the inhibition of IL-2 secretion.
Assays were performed in 96 well flat-bottom plates in a volume of 210 µl,
which included 190 µl of whole blood or PBMC (1 3 106 cells per ml),
10 µl of PMA (1 µg per ml) and ionomycin (20 µg per ml) mixture, and
10 µl of serially diluted ABT-281. Plasma or tissue culture supernatants
were collected 24 h later and IL-2 concentrations determined by ELISA.
Porcine MLR assay Fifty milliliters of sodium heparinized venous blood
was drawn from four pigs and diluted with an equal volume of 0.9% saline.
PBMC were isolated by density centrifugation for preparation of responder
and stimulator cells as described above. MLR were performed as described
for the human MLR, using 100 µl of responder cells (2 3 106 cells per
ml) and 100 µl of stimulator cells (0.5–4 3 106 cells per ml).
Rat MLR assay Popliteal, inguinal, and mesenteric lymph nodes from
newly killed Lewis rats and spleens from Brown Norway rats were
aseptically removed. Single cell suspensions of splenocytes and lymphocytes
were prepared using forceps and a hemostat to macerate the tissues. Red
blood cells (RBC) in the splenocyte suspension were lysed by 2 min
incubation at ambient temperature in RBC lysis buffer containing 0.14 M
NH4Cl in 0.017 M Tris–HCl, pH 7.2. Responder cells from Lewis rat
lymph nodes and stimulator cells from Brown Norway rat spleens were
washed three times in RPMI-1640 medium and then sedimented at
400 3 g for 10 min. Stimulator cells were prepared as described for human,
and the assay was conducted in serum-free AIM-V medium supplemented
with 1% Antibiotic-Antimycotic solution and 50 µM 2-mercaptoethanol,
using an optimized cell ratio of 100 µl of responder cells (2 3 106 cells
per ml) and 100 µl of stimulator cells (1–2 3 106 cells per ml) and an
incubation period of 4 d.
Mouse MLR assay Spleens were aseptically removed from six to 10
newly killed C3H (C3H/HeNCrlBR) and BALB/C mice. Splenocytes
were prepared and the assay conducted as for rat, using an optimized cell
ratio of 100 µl of responder cells (4 3 106 cells per ml) and 100 µl of
stimulator cells (1 3 106 cells per ml).
Concanavalin A (Con A)-induced guinea-pig lymphocyte prolifera-
tion assay Spleens were aseptically removed from two to three newly
killed guinea-pigs. Single cell suspensions of splenocytes were prepared as
for rat using a 4 min incubation in lysis buffer to remove RBC. Splenocytes
were washed three times in RPMI-1640 medium and adjusted to 6.25 3 105
cells per ml in culture medium consisting of RPMI-1640 supplemented as
described for human MLR. Con A-induced proliferation reactions were
performed in a volume of 200 µl containing 20 µl of culture medium
with or without test compound, 160 µl of guinea-pig splenocytes and
20 µl Con A (20 µg per ml). Cultures were incubated for 3 d, pulse
labeled on the last day with [3H]thymidine, harvested and counted as
previously described.
Inhibition of cytokine secretion Serially diluted ABT-281 was added
to 96 well plates with PBMC in RPMI-1640 medium at 1 3 106 cells
per ml. PMA and ionomycin were added to effect 10 ng per ml and
500 ng per ml concentrations, respectively. Supernatants from these cultures
were collected 24 h later after centrifugation and stored at –80°C until
use. Concentrations of IL-2 and IFN-γ in the supernatants were determined
by ELISA. For assessing inhibition of IL-4 and IL-5 secretion in T cells
by ABT-281, CD41 T cells were isolated from PBMC using a T cell
subset enrichment column (R&D Systems, Minneapolis, MN). Purified
CD41 T cells were cultured with serially diluted ABT-281 and PMA at
10 ng per ml in plates previously coated with a 100 ng per ml solution of
anti-CD3 antibody (Immunotech, Westbrook, ME). Supernatants were
collected after centrifugation 40 h later. IL-4 and IL-5 concentrations in
the supernatants were determined by ELISA.
Mouse contact hypersensitivity The rodent assays were adapted from
published methods (Corsini et al, 1979). CD1 mice were sensitized on the
shaved abdomen with 20 µl of 0.5% 2,4-dinitrofluorobenzene (DNFB) in
a vehicle consisting by volume of 95% acetone/5% olive oil (95:5) on days
0 and 1. On day 5, groups of 10 mice were challenged with 0.2% DNFB
in 95:5, with or without codissolved drug, 10 µl on both the internal and
external surface of both ears. Mice were killed 24 h post-challenge, and a
7 mm diameter circle punched from each ear was weighed immediately
on a microbalance. The mean ear plug weight from naı¨ve peer mice
challenged with 0.2% DNFB in 95:5 were used as background control
and percentage inhibition was calculated using the following equation:
100 – [(experimental ear plug weight) – (mean naı¨ve ear plug weight)]/
[(mean sensitized vehicle control plug weight) – (mean naı¨ve ear plug
weight)] 3 100. ED50 values were derived by simultaneous least squares
regression analysis.
Guinea-pig contact hypersensitivity Guinea-pigs, six per group, were
sensitized on the dorsal surface of one ear pinna with 50 µl of 10% DNFB
in 50% acetone:50% olive oil on day 0, and then on the opposing ear on
day 1. On day 5, animals were shaved and challenged with 0.5% DNCB
in 95:5, with or without codissolved drug, 15 µl per site, 4.8 µl per cm2,
on the dorsolateral surface (Hsieh et al, 1996). Naı¨ve animals were
challenged with DNCB and served as nonspecific controls. The response
was scored visually in blinded fashion 24 h after challenge (0, no change;
0.5, questionable erythema; 1, faint or scattered erythema; 2, mild, confluent
erythema; 3, moderate erythema without edema or induration; 4, strong
erythema with uniform induration or edema; 5, severe erythema with
induration or edema, plus ulceration). Data were calculated as for mouse
contact hypersensitivity.
Swine contact hypersensitivity Groups of six to 12 pigs were sensitized
with 10% DNFB in acetone/DMSO/olive oil (45:5:50 by volume) to the
shaved outer aspect of both ears and bilateral sites on the lower abdomen,
100 µl per site, on day 0, with a secondary application of 5% DNFB in
45:5:50 to the internal pinna and lower thorax on day 3. On day 9, pigs
were restrained on a webbed canvas cart and the test area carefully shaved
with an electric clipper using a no. 40 blade. A pilot challenge with 0.1,
0.15, and 0.2% 1-chloro-2,4-dinitrochlorobenzene (DNCB) in acetone/
olive oil vehicle (95:5 by volume), 3.8 µl per cm2, was used to determine
conditions for obtaining a submaximal average response in each animal
cohort. In all cases, pigs were scored by a blinded observer, 24 h post-
challenge on a scale from 0 to 4 (0, no change; 0.5, questionable erythema;
1, faint or scattered erythema; 2, moderate erythema without induration
or edema; 3, strong erythema with focal areas of edema or induration;
4, extreme erythema with uniform induration or edema), and pigs having
a mean DNCB control score , 1.5 were excluded (Hsieh et al, 1997).
Based on their pilot response scored on day 10, animals were stratified
into two groups having comparable mean scores, challenged on duplicate
sites with DNCB in 95:5, with or without codissolved drug, and scored
on day 11. Scores for each challenge site were compared with the average
of the control spots treated with DNCB alone on the same pig, and
expressed as percentage inhibition.
For intravenous studies, compounds were diluted in 10% ethanol, 40%
propylene glycol, 2% cremophor EL, and 48% dextrose (5%) in water
(EPC vehicle) and pigs were dosed with 1 ml per kg, 30 min before
topical challenge with DNCB in 95:5. Scores measured on day 11 were
compared with the previous pig-specific day 10 average control scores. To
assess clinical formulations, DNCB in 95:5 was applied on day 10 to
triplicate dorsolateral sites, followed 30 min later by the application of drug
formulation to give a uniform overlayer of 5 mg per cm2. Scores on each
pig were compared with the average of the control spots treated with
DNCB alone.
Rat i.v. pharmacokinetic screening Drugs were freshly prepared in
EPC vehicle prior to administration of 5 mg per kg (1 ml per kg body
weight) via jugular vein to Sprague–Dawley rats under light inhalation
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anesthesia with a 60% CO2/40% O2 mixture. Blood samples, collected by
orbital sinus (retro-orbital plexus) bleeding in heparinized tubes at 0.25, 2,
and 4 h, were hemolyzed by the addition of 3 volumes of 20% methanol
in water. Drugs were extracted from blood contaminants utilizing liquid–
liquid extraction with ethyl acetate/hexane (1:1 by volume). Samples were
centrifuged at 500 3 g for 10 min and a constant volume of the organic
layer was transferred to a conical centrifuge tube and evaporated to dryness
with a gentle stream of dry air over low heat (µ37°C). Extracts were
reconstituted with 40% acetonitrile in water with vortexing. Separations
of the compounds of interest from the coextracted components following
a 100 µl injection were achieved on an Inertsil ODS-2, reversed phase
analytical HPLC column (4.6 3 50 mm) from GL Sciences (Aston,
PA), using a mobile phase containing 45:5:50 acetonitrile/methanol/0.1%
trifluoroacetic acid/0.01 M tetramethylammonium perchlorate mixture at
a flow rate of 1.0 ml per min with UV detection at 205 nm. The
temperature of the HPLC column was maintained at 70°C to promote
peak sharpness. Drug concentrations were estimated in reference to whole
blood standards, which were prepared with known drug concentrations,
extracted, and analyzed concurrently.
Swine i.v. pharmacokinetics Drugs were freshly prepared in EPC
vehicle prior to i.v. administration. Blood samples were obtained from the
convergence of vessels at the right lateral thoracic inlet at 0, 0.25, 0.5, 1,
2, 4, 6, 9, 12, 24, 48, 72, and 96 h post-injection. Blood samples were
immediately placed on ice. A 1.0 ml aliquot of blood was hemolyzed with
0.4 ml of 20% MeOH in water containing an internal standard. The
hemolyzed samples were extracted with a mixture of ethyl acetate and
hexane (1:1 vol/vol, 5.0 ml). The organic layer was evaporated to dryness
with a stream of dry air over low heat. Samples were reconstituted in
MeOH/H2O (1:1, 150 µl) and analyzed on a Perkin Elmer API 300
liquid chromatography mass spectrophotometer. Samples were kept frozen
(–20°C) until analysis and kept cool (4°C) during the run. Compounds
were separated from contaminants using a 50 µl injection and a TMC-
basic 5 µm 150 3 2 mm column at 50°C. The mobile phase contained
60% acetonitrile in 100 mM NH4OAc (adjusted with glacial acetic acid to
pH 5.5) at a flow rate of 0.6 ml per min. The limit of quantitation for
both compounds was µ0.1 ng per ml.
Swine topical pharmacokinetics Pigs were restrained as for contact
hypersensitivity and shaved over a more extensive area. Drugs diluted in
95% acetone/5% olive oil vehicle were applied topically on the dorsolateral
surface, 3.8 µl per cm2, covering 25% of total body surface area (swine
surface area 5 0.097 3 [kg body weight]0.633). Blood samples were
obtained at 0, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h post-application and
analyzed as above.
Rat popliteal lymph node (PLN) hyperplasia assay Spleens from
Brown-Norway rats were harvested aseptically, splenocytes expressed by
compression with a hemostat in sterile DPBS, red blood cells lysed with
Tris (0.16 M) buffered ammonium chloride (0.17 M) buffer, washed twice
(400 3 g) in DPBS, irradiated (20 Gy), washed in DPBS, and suspended
in DPBS at 5 3 107 cells per ml. On day 0, recipient Lewis rats (170 g)
were injected subcutaneously into the plantar surface of the right hindpaw
with 0.1 ml of the splenocyte suspension. Compounds were prepared in
EPC vehicle and dosed once daily, 2 ml per kg, on days 0–3. Recipients
were killed on day 4 and PLN from both hind limbs from vehicle control
rats, or the right PLN from drug-treated rats, were dissected free and
weighed individually on a microbalance. The average weight of PLN from
the left leg of vehicle-treated animals was used as the background control
(Mollison et al, 1993), and percentage inhibition was calculated using the
Table I. Inhibition of T cell proliferation by ABT-281
IC50 (nM) (95% CL)
a
Human Rat Mouse Guinea pig Swine
Drug MLR MLR MLR Con A MLR
Ascomycin 0.32 0.35 0.35 0.59 0.86
(0.21–0.47) (0.20–0.53) (0.06–0.98) n.a. (0.58–1.26)
n 5 23 n 5 21 n 5 3 n 5 1 n 5 30
ABT-281 1.47b 0.45 1.13 0.87 1.28
(1.06–2.09) (0.25–0.73) (0.44–3.11) (0.36–1.97) (0.76–2.24)
n 5 9 n 5 4 n 5 2 n 5 2 n 5 8
a95% confidence limits; n 5 number of donor results pooled; n.a., not available.
bp , 0.05 versus ascomycin.
following equation: 100 – [(experimental PLN weight) – (mean vehicle
control left PLN weight)]/[(mean vehicle control right PLN) – (mean
vehicle control left PLN weight)]. ED50 values were derived by simultan-
eous least squares regression analysis.
RESULTS
ABT-281 potently inhibits T cell function across species To
support the in vivo studies of ABT-281, its potency compared with
the ascomycin parent compound was determined in the MLR
using T cells from the various species under study. Peripheral
blood from histoincompatible donors was used as a source of swine
and human stimulator and responder cells, and splenocytes from
major histocompatibility complex mismatched inbred strains were
harvested for the rat and mouse assays. Because of the difficulty in
obtaining histoincompatible guinea-pig strains, precluding use of
an MLR, a mitogen-induced proliferation of splenocytes by Con
A was used. As shown in Table I, ABT-281 inhibited T cells from
all species and had a potency within several-fold of ascomycin with
human cells. There was not a statistically significant difference
between the two compounds in rat, mouse, guinea-pig, or swine.
ABT-281 inhibits production of both Th1 and Th2
cytokines Inhibition of human T cell cytokine production by
ABT-281 is shown in Fig 2. Stimuli were chosen to optimize
Figure 2. Inhibition of cytokine production by ABT-281 vs.
ascomycin. IL-2 and IFN-γ biosynthesis of human PBMC were stimulated
by PMA plus ionomycin. IL-4 and IL-5 production by purified human
CD41 T cells was induced by PMA plus anti-CD3 (see Materials and
Methods). d, Ascomycin; s, ABT-281; data are mean 6 SEM; n 5 3–4.
VOL. 112, NO. 5 MAY 1999 CYTOKINE INHIBITOR FOR INFLAMMATORY DISEASES 733
cytokine biosynthesis in the respective cell preparations. The key
Th1 regulatory cytokines, IL-2 and IFN-γ, as well as the Th2
cytokines, IL-4 and IL-5, were all potently inhibited by ABT-281,
as summarized in Table II. Interestingly, whereas ABT-281 potency
was µ5-fold lower than ascomycin in the human MLR (Table I),
it was within 2-fold of ascomycin in all of the cytokine determina-
tions. The latter results also agree well with the potency relationship
observed across species in the MLR or Con A-induced proliferation
assays, where there was typically only a 2-fold difference. Compared
with the IC50 of 2.6 nM for ABT-281 inhibition of IL-2 shown
in Table II where it was assayed along with IFN-γ, a separate
inhibition study of IL-2 produced by isolated PBMC also gave a
potent ABT-281 IC50 of 0.98 ng per ml, which is equivalent to
1.2 nM (Table V). Thus, inhibition of human T cell functional
responses by ABT-281 appears to be little different from ascomycin.
ABT-281 is topically active in a stringent swine contact
hypersensitivity model T cell dependent contact hypersensi-
tivity responses were induced in several species using a contact
sensitizer and used to compare drug potencies in vivo. Mice
sensitized with dinitrofluorobenzene (DNFB) were subsequently
challenged by applying DNFB on the surface of the ear with or
without test compound. The resulting edema response gave a
maximal increase in ear weight that reached a peak at 24 h. Guinea-
pigs were tested by sensitizing with DNFB on the ears, challenging
sites on the back of the animal using dinitrochlorobenzene (DNCB),
a cross-reacting hapten that is less directly irritating to skin, and
scoring the lesions visually for erythema and swelling. A test
protocol similar to that used for guinea-pig was established for
swine. Dose–response studies were done to determine the topical
potencies of ABT-281 and ascomycin in comparison with cyclo-
sporine.
As shown in Table III, the topical potency of ascomycin varied
among species. Compared with its best potency, obtained in the
mouse, there was a 6-fold reduction in the guinea-pig and a
Table II. ABT-281 inhibition of cytokine release from
human peripheral blood T cells
IC50, (nM) (6 SEM)
Cytokines Ascomycin ABT-281
Th1a IL-2 1.1 6 0.15 2.6 6 0.53
IFN-γ 1.2 6 0.13 2.1 6 0.55
Th2b IL-4 1.1 6 0.25 2.2 6 0.24
IL-5 1.5 6 0.29 3.2 6 1.00
aCytokines from PBMC stimulated with PMA plus ionomycin measured by ELISA
(see Materials and Methods); n 5 3.
bCytokines from purified circulating CD41 T cells stimulated with PMA plus
anti-CD3 measured by ELISA (see Materials and Methods); n 5 3 for IL-2; n 5 4
for IFN-γ.
Table III. Drug potency for inhibition of contact
hypersensitivity in swine versus rodents
Topical ED50 (%)
a (95% CL)b
Species Cyclosporine Ascomycin ABT-281
Mouse 0.078 0.004 0.071
(0.019–0.18) (0.002–0.006) (0.031–0.144)
n 5 10 n 5 10 n 5 10
Guinea-pig 1.42 0.026 0.041
(1.0–2.2) (0.017–0.045) (0.009–0.082)
n 5 6 n 5 6 n 5 6
Swine ..3 0.53 0.57
(0.33–0.86) (0.44–0.75)
n 5 6 n 5 18 n 5 18
aSimultaneous application with DNFB or DNCB in acetone/olive oil (see Materials
and Methods).
b95% confidence limits; n 5 number of individual animals pooled.
further 20-fold potency loss when tested topically in swine contact
hypersensitivity. These differences are likely attributable to increas-
ing skin barrier differences affecting drug penetration, as the in vitro
potency of ascomycin was similar across species (Table I). Consistent
with this interpretation is the relative topical potency of cyclosporine
in the various species. Cyclosporine was tested as a reference agent
whose topical delivery is similarly challenging due to its high
molecular weight (1202 vs 792 and 840 for ascomycin and ABT-
281, respectively). The in vitro potency of cyclosporine was found
to be similar across species in Con A-induced proliferation assays
(data not shown). While relatively potent in the mouse in vivo,
cyclosporine was 18-fold weaker in guinea-pig and produced no
statistically significant inhibition of contact hypersensitivity in swine
at concentrations as high as 3% (Table III). In comparison with
the potency shift seen with ascomycin, given the larger molecular
weight of cyclosporine, a reduction in swine potency of more than
20-fold compared with guinea-pig is not surprising. These results
confirm the lack of cyclosporine topical activity reported in swine
(Meingassner and Stu¨tz, 1992), and support the use of the swine
model as a more human-like species with regard to topical drug
delivery by providing a stringent test of skin penetration for
topical agents.
Consistent with its T cell effects in vitro, ABT-281 showed potent
topical inhibitory activity comparable with ascomycin in both
guinea-pig and swine (Table III). The topical potency of ABT-
281 in mouse was lower, as was seen with mouse T cells in vitro
(Table I). There was not a significant difference in topical potency
between ABT-281 and ascomycin in guinea-pig or swine. Although
ABT-281 showed a reduced topical potency when applied to swine
skin as compared with rodent, the fact that ABT-281 was efficacious
in swine suggests that, in contrast to cyclosporine, it will be capable
of showing efficacy in human skin.
ABT-281 has topical efficacy in swine superior to reference
agents The topical potency of ABT-281 in an ointment formula-
tion is shown in Fig 3 in comparison with reference drugs currently
used for skin disease therapy, which were applied in their clinical
formulations. The super-potent corticosteroids, Temovate and
Diprolene, achieved at best a partial inhibition of the visual score.
There was a rank order effectiveness that corresponded reasonably
well with the potency class, established in humans using vaso-
constriction as a readout (Stoughton and Cornell, 1993). The
preparations weakest in clinical effectiveness were inactive, provid-
ing further support for the stringency of the swine model. Dovonex,
containing the vitamin D analog calcipotriene, was also inactive.
In contrast, The ABT-281 ointment was highly efficacious at both
test concentrations, achieving an inhibition of 90% compared with
a maximum of 59% with Temovate.
Figure 3. Efficacy of ABT-281 compared with reference agents for
inhibiting DNCB induced contact hypersensitivity in swine. All
agents were tested in their clinical formulations. Potency class rank of the
corticosteroids in human is indicated (Stoughton and Cornel, 1993). Bars
show mean 6 SEM; n 5 6–9; *p , 0.05 versus untreated controls.
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ABT-281 has a more rapid pharmacokinetic elimination
than ascomycin in rat and swine, which reduces systemic
exposure following topical delivery Interest in ABT-281
stemmed from its initial testing in the rat, where it was found
to have weak systemic immunomodulatory activity. Blood level
measurements following systemic administration were done to
determine if there was a pharmacokinetic explanation. Indeed,
Fig 4 shows that drug levels in whole blood following i.p.
administration of ABT-281, while high initially, declined at a much
faster rate than ascomycin. More thorough pharmacokinetic studies
were done in pigs to determine the rate of elimination following
i.v. administration in a single bolus dose. As shown in Table IV,
the terminal elimination half-life (t1/2) of ABT-281 was approxi-
mately three times shorter and the rate of clearance almost 6-fold
greater than with ascomycin.
ABT-281 blood levels after widespread topical exposure
are undetectable Because rapid elimination of absorbed drug
following topical use is a desirable attribute, topical pharmacokinetic
studies were done to help determine the extent of systemic
absorption and the steady-state whole blood levels of drug following
Figure 4. Rate of elimination of ABT-281 versus ascomycin following
i.v. injection in the rat. The concentration of drug in the blood following
i.v. administration was measured at several time points as a screen to
identify ascomycin analogs with more rapid clearance. d, ascomycin;
s, ABT-281; data are mean 6 SEM; n 5 3.
Table IV. Pharmacokinetics of ABT-281 and ascomycin in swine
Drug Dose (mg per kg, i.v.) Vc (liters per kg) Vβ (liters per kg) AUC0-` (ng per h per ml) Clβ (l per h per kg) t1/2 (h)a
Ascomycin 0.15 0.57 1.6 1487.3 0.10 11.1
ABT-281 0.15 0.62 4.1 264.4 0.58 4.8
aHarmonic mean; n 5 3.
Table V. Blood levels of ABT-281 following extensive topical application in swine versus T cell potency in whole blood
In vitro T cell potencya Swine topical pharmacokineticsb
Drug Human PBMC IC50 (ng per ml) Human whole blood IC50(ng per ml) Swine whole blood (ng per ml) measured at
(95% CL) (95% CL 1, 2, 4, 6, 8, 12, 24, 48, or 72 h
ABT-281 0.98 (0.79–1.22) 34.2 (25.7–47.0) , 0.1
aInhibition of PMA plus ionomycin induced IL-2 (see Materials and Methods).
b3% ABT-281 applied on 25% body surface area (see Materials and Methods).
extensive topical application. ABT-281 was applied to pigs as a 3%
solution in acetone/olive oil over 25% of the body surface area.
Despite the high applied concentration of ABT-281 relative to its
topical ED50 (0.6%), blood levels of the drug remained below
0.1 ng per ml for up to 72 h (Table V), consistent with an ongoing
rapid systemic clearance. Included for comparison are the ABT-
281 potencies for inhibiting production of T cell IL-2 determined
both for purified human PBMC in culture and in the original
undiluted whole blood sample from the corresponding donors.
The IC50 of 0.98 ng per ml (1.2 nM) for inhibiting IL-2 production
in PBMC was similar to the potency in human MLR using isolated
PBMC (Table I) and a variety of other cytokines (Table II). The
human whole blood potency was substantially lower, presumably
the result of drug binding to plasma proteins and red cell constitu-
ents, and should more closely resemble the blood levels needed for
the drug to exert a pharmacologic effect in vivo. These results show
that if the pig is predictive of the topical pharmacokinetics and rate
of systemic clearance of ABT-281 in human, the blood levels
following extensive topical application will likely be far below the
concentration required to inhibit the function of circulating T cells.
ABT-281 systemic activity is weak compared with ascomycin
in the rat PLN following i.p. administration The PLN assay
was used as an in vivo correlate of the MLR, as it measures
lymphoproliferation over a similar time course, and thus is well
suited for measuring the in vivo activity of agents such as ascomycin
analogs. The assay employed inbred rat strains with a defined
histocompatibility mismatch. Donor spleen cells were irradiated to
prevent a graft-versus-host response, and injected subcutaneously in
the plantar surface of the foot of recipient animals. This results in
T cell proliferation and accumulation within the draining popliteal
lymph node over the course of the next 96 h (Twist and Barnes,
1973). Rats were dosed daily with compound and the popliteal
nodes were harvested and weighed to reveal any inhibition of
hyperplasia.
Testing in the PLN assay has served as a check on bioavailability
for members of the ascomycin series, and provided the initial
indication that ABT-281 might have a more rapid elimination than
ascomycin. As shown in Fig 5, the dose–response curve for ABT-
281 was shifted markedly to the right. Given that the T cell
potency of ABT-281 in the rat MLR was not significantly different
from ascomycin (Table I), the in vivo potency, shown in Table VI,
was µ10-fold less than expected. The in vivo potency difference is
consistent with the more rapid rate of systemic clearance for ABT-
281 observed in the pharmacokinetic studies, so that its rapid
elimination from the body reduces its effective potency. Less potent
systemic activity should be a significant advantage for a topical
agent. The pharmacologic effects of ABT-281 would thus be
confined more locally to the skin compared with ascomycin, and
the drug would appear to have less potential for affecting immune
responses elsewhere in the body when administered topically.
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ABT-281 inhibition of swine contact hypersensitivity is
potent with topical but weak with i.v. administration To
verify that the favorable 10-fold systemic potency difference
observed in the rat (Table VI) occurs in other species, the topical
activity of ABT-281 and ascomycin in swine, when given along
with a hapten challenge (Fig 6A), was compared with results when
the agents were given with a bolus i.v. injection directly into the
bloodstream of sensitized pigs 30 min before challenging dorsal
skin sites with DNCB hapten (Fig 6B). The dose–response curves
for ABT-281 and ascomycin given topically were indistinguish-
able. When given systemically, however, as seen with the rat PLN,
the dose–response curve for ABT-281 was shifted significantly to
the right. In this swine allergic contact dermatitis model, the
systemic potency of ABT-281 was 10-fold lower than ascomycin,
as summarized in Table VI. The marked difference in immuno-
modulatory potency with parenteral administration in vivo is much
greater than would be expected from the small, nonsignificant
difference between ascomycin and ABT-281 in their swine T cell
inhibitory activities observed in vitro (Tables I, II, and V). These
results in the pig represent a second measurement, along with the
rat PLN, showing evidence of less persistent systemic effects due
to the more rapid clearance of ABT-281, a significant advantage
compared with the parent compound ascomycin.
Figure 5. Inhibition of popliteal lymph node (PLN) hyperplasia in
the rat with systemic administration of ABT-281 versus ascomycin.
Systemic immunomodulatory activity was compared by administering the
compounds i.p. in rats challenged with a footpad injection of allogeneic
splenocytes to induce T cell accumulation and proliferation in the PLN.
d, ascomycin; s, ABT-281; data are mean 6 SEM; n 5 14.
Table VI. Systemic potencies of ABT-281 in rat and swine
Rat PLN Swine contact hypersensitivity
Drug ED50, mg per kg per day, i.p. (95% CL) ED50 ratio ED50, mg per kg, i.v. (95% CL) ED50 ratio
Ascomycin 0.33 1 0.26 1
(0.27–0.40) (0.23–0.30)
n 5 24 n 5 5
ABT-281 3.23 9.8a 2.74 10.4a
(1.91–6.72) (1.49–23.6)
n 5 24 n 5 11
ap , 0.05.
Figure 6. Inhibition of DNCB induced contact hypersensitivity in
swine with topical or systemic administration of ABT-281 versus
ascomycin. (A) Dose–response curves are shown for topical application
simultaneously with the DNCB skin challenge in acetone/olive oil. (B)
Drugs were given i.v. to groups of pigs 30 min before application of
DNCB to the skin. d, ascomycin; s, ABT-281; data are mean 6 SEM;
n 5 5–9.
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DISCUSSION
The role of cytokines in the pathogenesis of skin diseases has been
reviewed (Cooper, 1994; Funk and Maibach, 1994; Kondo and
Sauder, 1995; Griffiths and Voorhees, 1996; Grewe et al, 1998) and
cannot be discussed here in detail; however, key human observations
will be summarized. The Th1 character of psoriasis is supported
by the development of skin lesions in quiescent patients treated
with IL-2 for cancer therapy (Lee et al, 1998), and conversely, a
therapeutic effect, accompanied by a shift toward Th2 cytokine
expression patterns, was seen in psoriasis patients following
administration of the Th2 cytokine, IL-10 (Asadullah et al, 1998).
T cells cloned from psoriatic skin can variously produce IFN-γ,
TGF-β, IL-2, IL-3, IL-6, IL-8, and GM-CSF, although none of
these are singly responsible for T cell stimulation of keratinocyte
growth, which appears to involve IFN-γ in concert with other
cytokines (Strange et al, 1993). IL-7 is also present at elevated levels
in lesional psoriatic compared with nonlesional and normal skin
(Bonifati et al, 1997). While B cells and monocytes can produce
IL-7, this cytokine is produced by both T cells and keratinocytes,
and is believed to be involved in their cross-regulation (Costello
et al, 1993). Data are also emerging on chemokine content
of psoriatic lesions. The IL-8/IL-8 receptor pathway has been
implicated in the disease (Lemster et al, 1995; Michel et al, 1996).
In addition to IL-8, the cytokines Mig (Goebeler et al, 1998)
and RANTES (Fukuoka et al, 1998) have been reported to be
abnormally expressed.
T cells from atopic dermatitis patients stimulated with specific
allergens are predominantly of the Th2 type, producing IL-4, IL-5,
and little IFN-γ (Wierenga et al, 1990). There is biochemical
evidence in atopic dermatitis of a monocyte/macrophage induced
shift in the Th1/Th2 ratio towards increased Th2 responses and
decreased IFN-γ production (Hanifin and Chan, 1995). Significance
of this apparent imbalance is supported by the therapeutic efficacy
of IFN-γ treatment (Hanifin et al, 1993). An increase in mRNA
for both IFN-γ and IL-4 has been observed in atopic dermatitis
lesions, and following successful treatment, message for IFN-γ, but
not IL-4, was down-regulated, suggesting the hypothesis that a
sequential shift from Th2 to Th1 cell involvement may occur in
the course of the disease (Grewe et al, 1994). A Th2 role is also
reflected in the overexpression of IL-10 (Ohmen et al, 1995) and
may underlie the elevation in circulating TNF-α, which is possibly
of mast cell origin (Sumimoto et al, 1992). IL-13, a cytokine that
can induce production of IgE and IgG4, is overexpressed in lesional
atopic dermatitis skin, but not in psoriasis (Van der Ploeg et al,
1997). Injection of allergens into the skin of atopic dermatitis
patients induces cutaneous expression of mRNA for the chemokines
MCP-3 and RANTES (Ying et al, 1995).
Allergic contact hypersensitivity has been associated with both
Th1 and Th2 cytokines in the skin. Biopsies after allergic patch
tests were found to have increased mRNA for IL-2 and IFN-γ, in
addition to IL-1α and TNF-α (Hoefakker et al, 1995). On the
other hand, T cell clones derived from skin lesions induced by
nickel sulfate in sensitive human subjects were found to produce
IL-4 either alone or in combination with IFN-γ (Werfel et al,
1997). IL-4 mRNA was also found in biopsied skin from contact
dermatitis patients (Ohmen et al, 1995). Mast cells, which participate
in the inflammatory cascade, are an abundant source of both Th1
and Th2 cytokines, as well as inflammatory mediators (Kondo and
Sauder, 1995).
In our studies, ABT-281, like its parent compound ascomycin,
was a potent inhibitor of T cell function. It blocked production of
a wide array of T cell cytokines, including the Th1 regulatory
cytokine IL-2, and IFN-γ, as well as the key Th2 regulatory
cytokines IL-4 and IL-5. This broad inhibitory profile explains the
T cell antiproliferative activity of ABT-281 and suggests that it
would be highly effective in treating not only allergic contact
hypersensitivity, as directly supported by our swine data, but also
the underlying diverse Th1/Th2 dependent immune dysregulations
manifested by psoriasis and atopic dermatitis. ABT-281 thus
represents a single agent that is likely to be efficacious in all three
diseases, as well as a number of other less prevalent immunologic
skin disorders.
The demonstration of ABT-281 single digit nanomolar inhibitory
potency in T cell functional assays is consistent with its ability to
exhibit topical activity, even in a stringent swine model of allergic
contact hypersensitivity, despite its relatively large size. We tested
cyclosporine as a reference compound, even though it is structurally
and mechanistically dissimilar, because its size limits its in vivo
activity. Our results confirm the lack of cyclosporine topical activity
reported in swine (Meingassner and Stu¨tz, 1992), which mirrors the
disappointing topical inactivity attributed to poor skin penetration in
human (Lebwohl et al, 1995). Cyclosporine has been shown to
penetrate the human stratum corneum barrier in vitro, but it has a
low permeation rate due to its large size and high lipophilicity
(Lauerma et al, 1997). Ascomycin and its analog, ABT-281, being
substantially more potent in their T cell effects and lower in
molecular weight, have a greater chance to exhibit topical activity
in human at practical concentrations. Pig skin has been appreciated
for many years to more closely resemble human skin than rodent
in terms of its anatomy and drug penetration barrier properties
(Bartek et al, 1972; Reifenrath et al, 1984; Nair et al, 1993). Because
the relative potencies for inhibiting T cells in vitro of ascomycin,
ABT-281, and cyclosporine are maintained across species, the
marked reduction in rank order topical potency: swine , guinea-
pig , mouse, seen with all three agents most likely reflects the
stringency of the skin barrier to drug penetration. The activity of
ABT-281 in this swine model, in contrast to the inactive cyclospor-
ine, suggests that its ability to penetrate the skin in appropriate
formulations will allow clinical efficacy.
Prospects for good ABT-281 therapeutic activity in skin diseases
as a topical agent are further illustrated by its superior efficacy
when tested in an ointment formulation in the swine model of
allergic contact hypersensitivity in comparison with reference
corticosteroids, which have been the focus of decades of research to
optimize potency and effective topical delivery (Fig 3). Comparing
absolute potencies of formulated topical agents is difficult because
the availability of only a fixed concentration of active drug precludes
carrying out dose–response studies. We, therefore, tested a number
of corticosteroids in their clinical formulations which cover a range
of defined topical potency ranking in human (Stoughton and
Cornell, 1993). The similar rank order of activity observed in the
swine and the lack of activity shown by the less potent steroids
further validated the usefulness of this model as a human-like skin
species and showed that ointment formulations can be successfully
tested without inducing artifactual effects on the DNCB response.
This was further illustrated by the lack of inhibition with Dovonex.
Although it can induce a normalization of immunologic and
inflammatory mediators over time in psoriasis, it is still not clear
whether this is a direct or indirect effect (Lea and Goa, 1996), and
its active agent, calcipotriol, has been found to be inactive in mouse
contact hypersensitivity (Garrigue et al, 1993). Thus, it was tested
in the swine contact hypersensitivity model as a negative control.
The fact that the super-potent Temovate and Diprolene oint-
ments barely achieved 50% inhibition in the swine model is
consistent with the difficulty of treating allergic contact hyper-
sensitivity with topical steroids (Stoughton and Cornell, 1993). In
contrast, the potent inhibition achieved with an ABT-281 ointment
even at the lower concentration of 0.3% suggests that it has
excellent clinical prospects for treating this disorder. Coupled with
the mechanistic information provided by the profile of T cell
cytokine inhibition exhibited by ABT-281, the ability to topically
deliver ABT-281 in the swine model supports a likely clinical
efficacy in atopic dermatitis and psoriasis as well as contact hyper-
sensitivity.
The relatively weak systemic potency of ABT-281 compared
with ascomycin illustrates a further advantageous property of ABT-
281 as a topical agent. The 10-fold lower potency following
systemic administration that was seen whether measuring the ability
of ABT-281 to inhibit a T cell response in the skin of swine or
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within lymph nodes of the rat was consistent with the more rapid
pharmacokinetic elimination of ABT-281. A similar rapid decline
in T cell inhibitory activity was observed in the circulation of
cynomolgus monkeys given ABT-281 intravenously (Mollison et al,
1998). This behavior confers a relative differential for achieving
potent topical immunomodulatory activity without affecting
immune responses elsewhere in the body following topical
absorption of the drug. In fact, the use of i.v. or i.p. bolus drug
administration, as we have done, may underestimate the safety
margin resulting from enhanced systemic clearance following topical
application, where drug uptake would be slower and reach lower
maximal levels.
Indeed, direct measurement of ABT-281 in the blood following
extensive topical application in swine showed that the rate of
clearance easily outpaced the systemic uptake of the drug as levels
were undetectable. In clinical use, the topical exposure might
well exceed the experimental conditions used here, i.e., a high
therapeutic dose on 25% body surface area. First, there might be
patients using the drug on a majority of the skin surface. Second,
some regions of the human body would likely have a lower barrier
to drug penetration than the dorsolateral surface of swine, as the
sensitivity to inhibition by clinical formulations of topical steroids
we observed suggests that the swine skin barrier to drug penetration
may be more stringent than human. Third, in disease states, there
may be a lowered barrier to drug penetration, in addition to sites
of excoriation, that enhance overall percutaneous absorption. If the
topical pharmacokinetics in swine resemble human blood level
uptake and clearance, however, there would be at least a 300-fold
safety margin to compensate for these potential sources of increased
systemic exposure before blood levels would reach even the IC50
level for inhibition of circulating T cells. Accordingly, systemic
effects of ABT-281 will likely be negligible. ABT-281 thus has a
very favorable overall profile for use as a novel topical therapeutic
agent for treatment of a wide range of skin diseases.
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